Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Rating of “Moderate Buy” from Brokerages

Revance Therapeutics, Inc. (NASDAQ:RVNCGet Rating) has received a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $37.90.

A number of research firms have issued reports on RVNC. Cowen raised their price target on shares of Revance Therapeutics from $55.00 to $65.00 in a research report on Thursday, September 8th. StockNews.com lowered shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 13th. Wells Fargo & Company lifted their target price on shares of Revance Therapeutics from $17.00 to $24.00 and gave the company an “equal weight” rating in a report on Thursday, August 25th. Cowen lifted their target price on shares of Revance Therapeutics from $55.00 to $65.00 in a report on Thursday, September 8th. Finally, The Goldman Sachs Group initiated coverage on shares of Revance Therapeutics in a report on Thursday, September 22nd. They set a “buy” rating and a $33.00 target price for the company.

Revance Therapeutics Stock Up 0.5 %

RVNC opened at $22.79 on Friday. Revance Therapeutics has a 12-month low of $11.27 and a 12-month high of $30.95. The company has a debt-to-equity ratio of 2.60, a current ratio of 5.56 and a quick ratio of 5.33. The firm has a 50 day moving average of $24.49 and a two-hundred day moving average of $19.49.

Insider Activity at Revance Therapeutics

In related news, SVP Dwight Moxie sold 11,000 shares of Revance Therapeutics stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $27.07, for a total value of $297,770.00. Following the sale, the senior vice president now owns 31,694 shares of the company’s stock, valued at approximately $857,956.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Revance Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in RVNC. State of New Jersey Common Pension Fund D acquired a new stake in Revance Therapeutics during the 1st quarter worth $3,902,000. Commonwealth Equity Services LLC boosted its stake in Revance Therapeutics by 22.7% during the 1st quarter. Commonwealth Equity Services LLC now owns 30,313 shares of the biopharmaceutical company’s stock worth $591,000 after purchasing an additional 5,598 shares during the last quarter. Prospera Financial Services Inc acquired a new stake in Revance Therapeutics during the 1st quarter worth $122,000. Advisor Group Holdings Inc. boosted its position in shares of Revance Therapeutics by 60.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 1,071 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its position in shares of Revance Therapeutics by 7.6% during the 1st quarter. Teacher Retirement System of Texas now owns 13,921 shares of the biopharmaceutical company’s stock valued at $271,000 after acquiring an additional 981 shares during the last quarter. Institutional investors and hedge funds own 77.08% of the company’s stock.

About Revance Therapeutics

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Featured Stories

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.